Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 77, Issue 3, Pages 243-255
Publisher
Elsevier BV
Online
2020-11-14
DOI
10.1016/j.jacc.2020.11.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
- (2020) Thomas A. Zelniker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
- (2020) Jagdeep S.S. Singh et al. DIABETES CARE
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
- (2020) Wilfried Mullens et al. ESC Heart Failure
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure
- (2020) Carlos G. Santos-Gallego et al. JACC-Cardiovascular Imaging
- Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
- (2019) Emelia J. Benjamin et al. CIRCULATION
- Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
- (2019) Roni Nielsen et al. CIRCULATION
- Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?
- (2019) Carlos G. Santos-Gallego et al. CARDIOVASCULAR DRUGS AND THERAPY
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Exercise Intolerance in Patients With Heart Failure
- (2019) Marco Giuseppe Del Buono et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The anti-inflammatory effects of SGLT inhibitors
- (2019) Álvaro García-Ropero et al. Aging-US
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
- (2019) Michael E. Nassif et al. CIRCULATION
- Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction
- (2019) Akshay S. Desai et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
- (2018) Eduardo Flores et al. CARDIOVASCULAR DRUGS AND THERAPY
- Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION
- (2018) Nancy Luo et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiopulmonary Exercise Testing
- (2017) Marco Guazzi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction
- (2017) Yashashwi Pokharel et al. JAMA Cardiology
- Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/ReperfusionCLINICAL PERSPECTIVE
- (2016) Carlos G. Santos-Gallego et al. CIRCULATION
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role
- (2014) Ugo Corrà et al. EUROPEAN JOURNAL OF HEART FAILURE
- Left Ventricular Remodeling in Heart Failure
- (2011) Marvin A. Konstam et al. JACC-Cardiovascular Imaging
- Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction
- (2010) Daniel G. Kramer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction
- (2008) Anil Verma et al. JACC-Cardiovascular Imaging
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started